HIGHLIGHTS
- who: Huilai Lv and colleagues from the Hospital, China Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang have published the article: The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma, in the Journal: (JOURNAL)
- what: The authors analyzed the patients who were followed up for more than one year and report the survival outcomes after a median follow-up of 21.1 months. The study was approved by the Ethics Committee of the hospital and conducted in accordance with the 2013 edition . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.